Digital Therapeutics Functional Dyspepsia Market 2034

Report Description

This report is updated with the latest market data and insights as of June 2026. Base year: 2025  |  Forecast period: 2026-2034

Digital Therapeutics Functional Dyspepsia Market Outlook

According to our latest research, the global Digital Therapeutics for Functional Dyspepsia market size in 2025 stands at USD 512 million, reflecting robust industry momentum. The market is projected to expand at a CAGR of 20.5% from 2026 to 2034, reaching an estimated USD 2.74 billion by the end of the forecast period. This growth is primarily driven by rising prevalence of functional dyspepsia, increasing adoption of digital health solutions, and a growing emphasis on patient-centric care. The market's upward trajectory is further supported by technological advancements and the integration of artificial intelligence in digital therapeutics platforms, which are transforming the management of gastrointestinal disorders globally.

Get Free Sample Report

The primary growth driver for the Digital Therapeutics for Functional Dyspepsia market is the escalating incidence of functional dyspepsia worldwide. Functional dyspepsia, characterized by chronic or recurrent pain and discomfort in the upper abdomen, affects a significant portion of the global population, particularly in urbanized regions. The rising awareness of the condition, coupled with the increasing burden of gastrointestinal diseases, has necessitated innovative approaches to management. Digital therapeutics offer non-invasive, evidence-based interventions that can be tailored to individual patient profiles, making them highly attractive for both patients and healthcare providers. Furthermore, the normalization of remote monitoring and telemedicine that accelerated during the COVID-19 pandemic has created a durable shift in care delivery, facilitating timely diagnosis and continuous management of functional dyspepsia. Conditions treated by adjacent solutions, such as those addressed by digital therapeutics for GERD, share overlapping patient populations and therapeutic frameworks, reinforcing the broader gastrointestinal digital health ecosystem.

Another critical factor fueling market growth is the evolution of digital health infrastructure and the proliferation of smart devices. The widespread availability of smartphones, wearable devices, and user-friendly health applications has empowered patients to actively participate in their healthcare journey. Digital therapeutics solutions for functional dyspepsia often leverage real-time data collection, symptom tracking, and personalized feedback, enhancing patient engagement and adherence to therapy. The integration of advanced analytics and artificial intelligence further enables predictive modeling and individualized treatment strategies, which are instrumental in improving clinical outcomes. Additionally, favorable reimbursement policies and increasing investment from both public and private sectors are supporting the commercialization and scalability of digital therapeutics platforms, paving the way for sustained market expansion.

Regulatory support and growing collaborations between technology companies and healthcare organizations have also played a pivotal role in propelling the market forward. Regulatory agencies in North America and Europe are progressively recognizing digital therapeutics as legitimate medical interventions, establishing clear guidelines for product approval and reimbursement. This has encouraged innovation and fostered a competitive landscape, leading to the development of highly sophisticated digital therapeutics solutions. Strategic partnerships between digital health startups, pharmaceutical companies, and healthcare providers are facilitating the integration of digital therapeutics into routine clinical practice, thereby expanding their reach and impact. The growing emphasis on value-based care and patient outcomes is expected to further drive adoption of digital therapeutics for functional dyspepsia through 2034.

In parallel with advancements in digital therapeutics for functional dyspepsia, there is growing interest in the application of solutions targeting chronic inflammatory bowel conditions such as ulcerative colitis. This condition, characterized by inflammation and ulcers in the colon, affects millions worldwide. Digital therapeutics offer promising solutions by providing personalized, non-invasive interventions that help manage symptoms, improve quality of life, and reduce reliance on traditional medication. These platforms often incorporate dietary management, stress reduction techniques, and symptom tracking, empowering patients to take an active role in treatment. As awareness and understanding of these overlapping gastrointestinal disorders grow, digital therapeutics are poised to play a crucial role in their integrated management.

From a regional perspective, North America currently dominates the market, accounting for approximately 43.5% of global revenue in 2025, followed closely by Europe at around 21.5% and Asia Pacific at 20.0%. The high adoption rate in North America is attributed to advanced healthcare infrastructure, high digital literacy, and proactive regulatory frameworks. Europe is witnessing significant growth due to rising healthcare digitization and supportive government initiatives. Meanwhile, Asia Pacific is emerging as a lucrative market, driven by a large patient pool, increasing healthcare expenditure, and rapid technological advancements. Latin America and the Middle East & Africa are also contributing to market growth as digital health ecosystems in these regions continue to mature. Overall, the global Digital Therapeutics for Functional Dyspepsia market is poised for substantial growth through 2034, with regional dynamics playing a crucial role in shaping market trends.

Product Type Analysis

The Digital Therapeutics for Functional Dyspepsia market is segmented by product type into software applications and devices. Software applications represent the largest and fastest-growing segment, accounting for approximately 72.5% of the 2025 market, owing to their accessibility, scalability, and ability to deliver personalized interventions. These applications typically include mobile apps, web-based platforms, and integrated cloud solutions designed to assist patients in managing their symptoms, tracking progress, and accessing educational resources. The proliferation of smartphones and high-speed internet connectivity has made it easier for patients to download and use these applications, leading to increased patient engagement and improved adherence to prescribed therapies. Software applications also enable healthcare providers to remotely monitor patient progress, adjust treatment plans, and provide timely interventions, thereby enhancing the overall quality of care.

Get Free Sample Report

Devices, on the other hand, include wearable sensors, smart gastrointestinal monitoring tools, and other connected medical devices that support the management of functional dyspepsia. While devices account for approximately 27.5% of the 2025 market compared to software applications, they are gaining traction due to their ability to provide objective, real-time physiological data. These devices can monitor parameters such as gastric motility, heart rate variability, and stress levels, which are crucial in understanding the underlying causes and triggers of functional dyspepsia. The integration of devices with software applications creates a comprehensive digital therapeutics ecosystem, allowing for seamless data sharing and enhanced patient-provider communication. As device technology continues to evolve, adoption is expected to increase, particularly in clinical settings and among patients requiring continuous monitoring.

The synergy between software applications and devices is driving innovation in the market. Many leading companies are focusing on developing integrated solutions that combine the strengths of both segments, offering holistic and data-driven approaches to disease management. For instance, wearable devices can automatically sync with mobile apps, providing patients and clinicians with real-time insights into symptom patterns and treatment efficacy. This integration not only improves clinical outcomes but also enhances user experience, making digital therapeutics more appealing to a broader patient population. The trend towards interoperability and seamless connectivity is expected to shape the future of product development. Notably, innovations developed for related conditions, including platforms addressing chronic fatigue syndrome through digital therapeutics, are informing product architecture and user engagement strategies in the functional dyspepsia space as well.

Despite the rapid growth of software applications, challenges such as data privacy concerns, regulatory compliance, and the need for robust clinical validation remain. Ensuring the security and confidentiality of patient data is paramount, given the sensitive nature of health information. Regulatory agencies are increasingly scrutinizing digital therapeutics products to ensure they meet stringent safety and efficacy standards. Companies operating in this space must invest in rigorous clinical trials, robust cybersecurity measures, and continuous product updates to maintain user trust and regulatory approval. Addressing these challenges will be critical to sustaining the growth and credibility of the Digital Therapeutics for Functional Dyspepsia market through 2034.

Report Scope

Therapy Type Analysis

The market for Digital Therapeutics for Functional Dyspepsia is segmented by therapy type into standalone and combination therapies. Standalone digital therapeutics refer to interventions delivered solely through digital platforms, without adjunctive pharmacological or physical therapies. This segment has gained significant traction due to its convenience, cost-effectiveness, and ability to deliver evidence-based behavioral interventions at scale. Standalone solutions are particularly popular among tech-savvy patients who prefer self-management and remote care. These therapies typically include cognitive behavioral therapy modules, symptom tracking, and lifestyle modification programs, which have demonstrated efficacy in reducing symptom severity and improving quality of life for patients with functional dyspepsia.

Combination therapies, which integrate digital therapeutics with traditional medical treatments such as pharmacotherapy or dietary interventions, are emerging as a promising approach for more complex cases. This segment is gaining momentum as healthcare providers recognize the value of a multi-modal approach to functional dyspepsia management. Combination therapies leverage the strengths of both digital and conventional treatments, providing comprehensive care that addresses both the physiological and psychological aspects of the disorder. For example, a patient may use a digital therapeutic app for symptom monitoring and behavioral modification while simultaneously receiving medication prescribed by a gastroenterologist. This integrated approach has been shown to enhance treatment adherence, optimize therapeutic outcomes, and reduce overall healthcare costs.

The adoption of combination therapies is further facilitated by advancements in interoperability and data integration. Digital therapeutics platforms are increasingly being designed to interface with electronic health records (EHRs), enabling seamless data exchange between patients, providers, and other stakeholders. This connectivity allows for more personalized and adaptive treatment plans, as clinicians can monitor patient progress in real time and make data-driven adjustments to therapy. The trend towards integrated care pathways is expected to drive the growth of the combination therapy segment, particularly in hospital and clinic settings where multidisciplinary teams collaborate on patient management.

The psychosocial dimension of functional dyspepsia management shares methodological overlap with solutions developed for mental health conditions. Platforms designed around approaches used in treating generalized anxiety disorder through digital therapeutics are informing the stress-management and cognitive behavioral modules now embedded within leading functional dyspepsia products. The integration of these mental health frameworks into gastrointestinal digital therapeutics reflects a broader trend toward holistic, mind-gut care strategies that resonates strongly with clinicians and patients alike in 2025.

Despite the benefits, the implementation of combination therapies presents certain challenges, including coordination of care, reimbursement complexities, and the need for robust clinical evidence to support efficacy claims. Healthcare providers must establish clear protocols for integrating digital therapeutics with existing treatment regimens, ensuring that all interventions are evidence-based and complementary. Payers and policymakers are also grappling with how to reimburse combination therapies, given their hybrid nature. Ongoing research and real-world evidence generation will be crucial in demonstrating the value of combination therapies and securing broader acceptance among clinicians, patients, and payers through the 2026-2034 forecast period.

Application Analysis

Within the Digital Therapeutics for Functional Dyspepsia market, applications are broadly categorized into indigestion management, symptom tracking, patient education, and others. Indigestion management represents the core application, as digital therapeutics platforms are specifically designed to address the hallmark symptoms of functional dyspepsia, such as bloating, early satiety, and upper abdominal pain. These solutions often incorporate evidence-based behavioral therapies, dietary guidance, and stress management techniques, all delivered through interactive digital interfaces. By providing patients with tailored interventions and real-time feedback, digital therapeutics empower individuals to take control of their symptoms, reduce reliance on medications, and improve their overall quality of life.

Symptom tracking is another critical application, enabling continuous monitoring of symptom patterns, triggers, and treatment responses. Digital therapeutics platforms typically include user-friendly interfaces for logging symptoms, dietary intake, physical activity, and medication adherence. Advanced analytics and machine learning algorithms can identify trends and correlations, helping both patients and clinicians understand the factors contributing to symptom exacerbation or relief. Symptom tracking not only supports personalized care but also facilitates early intervention, as clinicians can proactively address emerging issues before they escalate. This application is particularly valuable in remote care settings, where frequent in-person visits may not be feasible.

Patient education plays a vital role in the management of functional dyspepsia, as knowledge and self-awareness are key to effective self-management. Digital therapeutics platforms offer a wealth of educational resources, including articles, videos, interactive modules, and peer support forums. These resources help patients understand the nature of their condition, the rationale behind various treatment strategies, and the importance of lifestyle modifications. By fostering health literacy and self-efficacy, patient education modules contribute to better treatment adherence and improved clinical outcomes. Many platforms also provide personalized educational content based on individual patient profiles, further enhancing engagement and relevance.

Other applications within the Digital Therapeutics for Functional Dyspepsia market include mental health support, stress reduction, and integration with broader chronic disease management programs. Functional dyspepsia is often associated with psychological comorbidities such as anxiety and depression, which can exacerbate symptoms and complicate treatment. Digital therapeutics platforms increasingly incorporate modules for mindfulness, relaxation techniques, and cognitive behavioral therapy, addressing the psychosocial aspects of the disorder. Integration with chronic disease management programs allows for holistic care, as many patients with functional dyspepsia also suffer from other gastrointestinal or metabolic conditions. The versatility and adaptability of digital therapeutics platforms make them well-suited to address the complex and multifaceted needs of this patient population.

End-User Analysis

The end-user landscape for Digital Therapeutics for Functional Dyspepsia includes hospitals, clinics, homecare settings, and others. Hospitals represent a significant end-user segment, particularly for patients with severe or refractory symptoms who require multidisciplinary care. Large healthcare institutions are increasingly adopting digital therapeutics platforms to enhance patient engagement, streamline care pathways, and reduce hospital readmissions. Integration with electronic health records and other hospital information systems enables seamless data sharing and coordinated care, improving both clinical outcomes and operational efficiency. Hospitals are also leveraging digital therapeutics for remote monitoring and telehealth, expanding access to care for patients in underserved or remote areas.

Clinics, including gastroenterology and primary care practices, are another important end-user segment. Clinics often serve as the first point of contact for patients with functional dyspepsia, making them ideal settings for the deployment of digital therapeutics solutions. These platforms enable clinicians to efficiently assess symptoms, deliver personalized interventions, and monitor patient progress over time. The ability to remotely track symptoms and adjust treatment plans based on real-time data is particularly valuable in outpatient settings, where frequent follow-up visits may not be practical. Clinics are also well-positioned to participate in clinical trials and real-world evidence generation, supporting the ongoing validation and refinement of digital therapeutics products.

Homecare is an emerging and rapidly growing end-user segment, driven by the increasing preference for self-management and remote care. Digital therapeutics platforms designed for home use empower patients to manage their symptoms in the comfort of their own homes, reducing the need for frequent clinic visits and minimizing disruptions to daily life. Homecare solutions are particularly beneficial for patients with mild to moderate symptoms, as well as those with limited access to healthcare facilities. The convenience and flexibility of home-based digital therapeutics are driving adoption among a wide range of patient demographics, including the elderly and those with chronic comorbidities.

Other end-users include research institutions, pharmaceutical companies, and payers, all of whom play a role in advancing the adoption and integration of digital therapeutics for functional dyspepsia. Research institutions are actively involved in clinical trials and outcomes research, generating the evidence needed to support regulatory approval and reimbursement. Pharmaceutical companies are exploring partnerships with digital therapeutics providers to enhance their product portfolios and offer comprehensive care solutions. Payers are increasingly recognizing the value of digital therapeutics in reducing healthcare costs and improving patient outcomes, leading to greater inclusion of these products in reimbursement schemes. The diverse end-user landscape underscores the broad applicability and transformative potential of digital therapeutics in the management of functional dyspepsia.

Distribution Channel Analysis

The distribution channel for Digital Therapeutics for Functional Dyspepsia is segmented into online and offline channels. Online distribution channels, which include company websites, digital health platforms, and app stores, dominate the market due to their convenience, accessibility, and ability to reach a global audience. The rise of direct-to-consumer models has enabled patients to easily access digital therapeutics solutions from the comfort of their homes, bypassing traditional healthcare intermediaries. Online channels also facilitate rapid updates, real-time customer support, and seamless integration with other digital health tools, enhancing the overall user experience. The normalization of remote healthcare delivery since the pandemic has further entrenched online distribution as the preferred channel across all major markets.

Offline distribution channels, including hospitals, clinics, pharmacies, and medical device retailers, continue to play a vital role in certain markets and patient populations. These channels are particularly important for patients who require professional guidance in selecting and using digital therapeutics solutions, as well as those with limited digital literacy or access to online resources. Offline distribution also supports the integration of digital therapeutics into existing care pathways, enabling healthcare providers to recommend and prescribe these solutions as part of a comprehensive treatment plan. In some regions, offline channels are essential for regulatory compliance and reimbursement, as certain digital therapeutics products must be dispensed through licensed healthcare providers.

The interplay between online and offline distribution channels is shaping the competitive landscape of the Digital Therapeutics for Functional Dyspepsia market. Many leading companies are adopting omnichannel strategies, leveraging both digital and physical touchpoints to maximize reach and engagement. For example, a digital therapeutics provider may offer its app through online platforms while also partnering with hospitals and clinics to facilitate in-person onboarding and support. This hybrid approach ensures that patients receive the guidance and resources they need, regardless of their preferred channel or level of digital proficiency. The ability to seamlessly transition between online and offline channels is becoming a key differentiator in the market.

Despite the dominance of online channels, challenges such as the digital divide, data privacy concerns, and regulatory variability persist. Ensuring equitable access to digital therapeutics across diverse populations requires targeted efforts to bridge gaps in digital literacy, infrastructure, and affordability. Companies must also navigate complex regulatory environments, as requirements for online distribution and reimbursement vary by region and product type. Addressing these challenges will be critical to ensuring the continued growth and sustainability of the Digital Therapeutics for Functional Dyspepsia market through 2034.

Opportunities & Threats

The Digital Therapeutics for Functional Dyspepsia market is brimming with opportunities, particularly in the area of personalized medicine and patient-centric care. Advances in artificial intelligence, machine learning, and big data analytics are enabling the development of highly tailored digital therapeutics solutions that address the unique needs and preferences of individual patients. These technologies can analyze vast amounts of patient data to identify patterns, predict symptom flares, and recommend personalized interventions, significantly improving clinical outcomes. The growing focus on preventive care and early intervention further expands the potential applications of digital therapeutics, as these solutions can identify at-risk individuals and provide timely support before symptoms become severe. Additionally, the increasing acceptance of digital therapeutics by regulatory agencies and payers is opening new avenues for commercialization and reimbursement, encouraging innovation and investment in the sector.

Another major opportunity lies in the integration of digital therapeutics with broader healthcare ecosystems, including electronic health records, telemedicine platforms, and chronic disease management programs. This integration enables seamless data exchange, coordinated care, and holistic management of patients with functional dyspepsia and comorbid conditions. Strategic partnerships between digital health companies, healthcare providers, and pharmaceutical firms are facilitating the development of comprehensive care solutions that combine digital therapeutics with traditional medical interventions. The expansion into emerging markets, where the burden of gastrointestinal diseases is high and access to healthcare is limited, presents significant growth potential. Tailoring digital therapeutics solutions to the specific needs and preferences of diverse populations will be key to unlocking these opportunities and driving global market expansion through 2034.

Despite the numerous opportunities, the market faces several restraining factors, with regulatory and reimbursement challenges being the most prominent. The evolving regulatory landscape for digital therapeutics, characterized by varying requirements across regions and product categories, creates uncertainty for companies seeking to bring new products to market. Securing regulatory approval and reimbursement can be time-consuming and costly, particularly for innovative solutions that lack established precedents. Additionally, concerns related to data privacy, cybersecurity, and patient trust must be addressed to ensure widespread adoption. Companies must invest in robust clinical validation, transparent data practices, and ongoing stakeholder engagement to overcome these barriers and realize the full potential of digital therapeutics for functional dyspepsia.

Regional Outlook

Regionally, North America leads the Digital Therapeutics for Functional Dyspepsia market, accounting for approximately USD 223 million of global revenue in 2025, representing roughly 43.5% of the total market. The region's dominance can be attributed to its advanced healthcare infrastructure, high digital literacy rates, and proactive regulatory environment. The United States, in particular, has been at the forefront of digital health innovation, with a large number of startups, established companies, and academic institutions actively developing and deploying digital therapeutics solutions. The presence of favorable reimbursement policies and strong investor interest further supports market growth in the region. Canada is also making significant strides in digital health adoption, driven by government initiatives and increasing patient demand for remote care solutions.

Get Free Sample Report

Europe is the second-largest market, with a 2025 market size of approximately USD 110 million, representing around 21.5% of global revenue. The region is characterized by a strong emphasis on healthcare digitization, supportive regulatory frameworks, and a growing focus on value-based care. Countries such as Germany, the United Kingdom, and France are leading the adoption of digital therapeutics, supported by government initiatives and public-private partnerships. The European Union's Digital Single Market strategy and the implementation of the Medical Device Regulation (MDR) have created a conducive environment for the development and commercialization of digital therapeutics products. The market in Europe is expected to grow at a CAGR of approximately 21.0% through 2034, driven by increasing awareness of functional dyspepsia and the demonstrated benefits of digital health interventions.

Asia Pacific is emerging as a high-growth region, with a market size of approximately USD 102 million in 2025, accounting for roughly 20.0% of global revenue, and presenting significant potential for further expansion. The region's large and diverse population, increasing prevalence of gastrointestinal disorders, and rapid adoption of digital technologies are key growth drivers. Countries such as China, Japan, South Korea, and India are witnessing rising investment in digital health infrastructure and growing acceptance of digital therapeutics among both patients and providers. Government initiatives to promote healthcare innovation, coupled with the proliferation of smartphones and internet connectivity, are facilitating market growth. While Latin America and the Middle East & Africa each hold smaller shares at approximately 8.5% and 6.5% respectively, they present untapped opportunities as digital health ecosystems continue to develop and awareness of functional dyspepsia increases across these populations.

Competitor Outlook

The competitive landscape of the Digital Therapeutics for Functional Dyspepsia market is characterized by a mix of established healthcare technology companies, innovative startups, and strategic collaborations. The market is highly dynamic in 2025, with companies focusing on product innovation, clinical validation, and strategic partnerships to gain a competitive edge. Leading players are investing heavily in research and development to enhance the efficacy, usability, and integration capabilities of their digital therapeutics platforms. The emphasis on evidence-based solutions and real-world outcomes is driving companies to conduct robust clinical trials and generate high-quality data to support regulatory approval and reimbursement. The market is also witnessing increased merger and acquisition activity, as larger companies seek to expand their digital health portfolios and enter new geographic markets.

Intellectual property and proprietary technology are key differentiators in this market, with companies striving to develop unique algorithms, user interfaces, and data analytics capabilities. The ability to seamlessly integrate digital therapeutics platforms with existing healthcare systems, such as electronic health records and telemedicine platforms, is becoming increasingly important. Companies are also focusing on enhancing patient engagement and adherence through gamification, personalized content, and real-time feedback. The growing importance of interoperability and data security is prompting companies to invest in robust cybersecurity measures and compliance with international standards such as GDPR and HIPAA. The competitive landscape is further shaped by the entry of non-traditional players, such as technology giants and consumer electronics companies, who bring significant resources and expertise in digital innovation.

In addition to product innovation, companies are actively pursuing strategic partnerships and collaborations to expand their reach and impact. Partnerships with healthcare providers, pharmaceutical companies, and payers enable digital therapeutics companies to integrate their solutions into clinical care pathways, access new patient populations, and secure reimbursement. Collaborations with academic institutions and research organizations support the generation of clinical evidence and the development of new therapeutic modalities. The trend towards ecosystem-based approaches is fostering the development of comprehensive care solutions that address the multifaceted needs of patients with functional dyspepsia. Companies are also engaging with patient advocacy groups and professional societies to raise awareness and promote the adoption of digital therapeutics.

Some of the major companies operating in the Digital Therapeutics for Functional Dyspepsia market include Mahana Therapeutics, Bold Health, MetaMe Health, Oshi Health, Click Therapeutics, Kaia Health, Twill (formerly Happify Health), WellDoc, DarioHealth, SilverCloud Health (Amwell), Sidekick Health, Cara Care (HiDoc), Gastro Girl, Vivante Health, and Iterative Health. Mahana Therapeutics is a recognized leader in digital therapeutics specifically for gastrointestinal disorders, offering clinically validated cognitive behavioral therapy-based solutions for irritable bowel syndrome and related functional conditions including functional dyspepsia. Bold Health and MetaMe Health are focused exclusively on gut-brain digital therapeutics, bringing targeted behavioral intervention platforms to market that address the neurological and psychological underpinnings of functional gastrointestinal disorders. Oshi Health combines digital therapeutics with access to specialized gastroenterology care teams, creating a comprehensive virtual care model. Click Therapeutics and Kaia Health bring strong AI and machine learning capabilities to their platforms, enabling highly personalized therapeutic pathways.

Twill, WellDoc, and DarioHealth each bring proven digital health infrastructure and significant real-world deployment experience, with established relationships with payers and employers that facilitate broad patient access. SilverCloud Health, now operating within the Amwell ecosystem, contributes validated digital mental health modules that are directly applicable to the psychosocial components of functional dyspepsia management. Sidekick Health and Cara Care (HiDoc) are notable for their consumer-facing engagement models and strong presence in the European market. Gastro Girl and Vivante Health focus specifically on digestive health digital therapeutics, addressing a gap in the market for condition-specific solutions. Iterative Health applies AI-driven analytics to gastrointestinal disease management, bridging diagnostics and therapeutics in a way that is increasingly relevant to the functional dyspepsia space. These companies are distinguished by their commitment to clinical validation, user-centric design, and strategic collaborations that are collectively advancing the standard of care for patients with functional dyspepsia as the market moves through 2025 and into the 2026-2034 forecast period.

Key Players

• Mahana Therapeutics
• Bold Health
• MetaMe Health
• Oshi Health
• Click Therapeutics
• Kaia Health
• Twill (formerly Happify Health)
• WellDoc
• DarioHealth
• SilverCloud Health (Amwell)
• Sidekick Health
• Cara Care (HiDoc)
• Gastro Girl
• Vivante Health
• Iterative Health